MS drug ofatumumab may shield brain cells, lab study suggests
NCT ID NCT05171972
First seen May 16, 2026 · Last updated Jun 11, 2026 · Updated 5 times
Summary
This study looked at whether a multiple sclerosis (MS) drug called Ofatumumab (Kesimpta) can make immune cells less toxic to brain cells. Researchers took blood samples from 40 people with relapsing-remitting MS before and after 6 months of treatment. They tested if the chemicals released by immune cells after treatment were less damaging to mouse brain cells grown in a dish. The goal was to understand how the drug works, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING REMITTING MULTIPLE SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Southern California
Los Angeles, California, 90089, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.